Lenvatinib, una nueva primera línea en carcinoma hepatocelular: estudio REFLECT

9 / 27

1. Kudo M et al. Lancet. 2018;pii:S0140-6736(18)30207–1.
REFLECT TRIAL: Patient Characteristics
*Based on masked independent imaging review.
BCLC = Barcelona Clinic Liver Cancer; ECOG-PS = Eastern Cooperative Oncology Group Performance Status; EHS = extrahepatic spread;
MVI = macroscopic portal vein invasion.
Characteristic Category Lenvatinib
(N=478)
Sorafenib
(N=476)
Total
(N=954)
Child-Pugh
class, n, %
A 475 99% 471 99% 946 99%
B 3 1% 5 1% 8 1%
MVI, n, %
Yes 109 23% 90 19% 199 21%
No 369 77% 386 81% 755 79%
EHS, n, %
Yes 291 61% 295 62% 586 61%
No 187 39% 181 38% 368 39%
ECOG-PS, n, %
0 304 64% 301 63% 605 63%
1 174 36% 175 37% 349 37%
MVI, EHS, or
both, n, %
Yes 329 69% 336 71% 665 70%
No 149 31% 140 29% 289 30%
Underlying
cirrhosis*, n, %
Yes 356 74% 364 76% 720 75%
No 122 26% 112 24% 234 25%
BCLC stage, n,
%
B (intermediate stage) 104 22% 92 19% 196 21%
C (advanced stage) 374 78% 384 81% 758 79%